Like for extraordinary speed! And Yellow Medicine heavy tumor new drug Sutaida ® wholesale goods only half a month

On January 14, 2021, the first shipment ceremony of Sotaida (Sovantini Capsules), independently developed by He Huang Pharmaceuticals, was held in Suzhou Park, and the first Sutaida (Sovantini Capsules) was officially shipped to all parts of the country.
This means that Sutada (Sovantini capsule) has been approved by the State Drug Administration of China on December 30, 2020 for the treatment of non-pancreatic neuroendocrine tumors, only half a month into clinical use, providing new treatment options for non-pancreatic neuroendocrine tumor patients in China.
not only that, but a team of about 400 oncologists, which has covered more than 2,000 hospitals across the country, has been in place to bring Sutada (Sovantini capsules) to Chinese patients at an extraordinary rate.
Sutada (Sovantini capsule) was approved for the market, non-pancreatic neuroendocrine tumor patients ushered in local innovation target drug days ago, Sutada (Sovantini capsule) was officially approved by China's State Drug Administration (NMPA) for the treatment of non-pancreatic neuroendocrine tumor (NET).
compared to other neuroendocrine tumor therapies available on the market, Suteda (Sovantini capsule) has a unique mechanism of action that inhibits angiogenesia while regulating the body's immune response to tumor cells.
Sutaida? (Sovantini capsule) was approved based on the results of a Chinese Phase III clinical trial SANET-ep in the treatment of patients with advanced non-pancreatic neuroendocrine tumors (clinicaltrials.gov registration number NCT02588170).
results showed that the medium progression-free survival of patients in the Sutada (Sofantini capsule) treatment group was significantly extended to 9.2 months, a 2.4-fold increase over the 3.8 months in the placebo group.
besides, Sutaida? (Sovantini capsules) reduced the risk of disease progression or death by 67% in patients with non-pancreatic neuroendocrine tumors.
positive results of the study were presented in oral presentation at the 2019 annual meeting of the European Society of Oncology (ESMO) and published in September 2020 in the Lancet Oncology, an international authoritative academic journal.
Suteda (Sovantini capsule) reached a predetermed endpoint in the mid-term analysis and ended early in two key Phase III. Studies in the late pancreatic NET and non-pancreatic NET populations.
After 14 years of exploration, Soteda (Sovantini capsule) became the largest breakthrough and advance of the year in net drug therapy, and also marked the patient's hope - ushering in the first anti-angiogenesic target drug to cover all sources of NET.
it's worth noting that, unlike previous innovative drugs, Chinese patients tend to lag behind those in Europe and the United States for years or more before they can be used, Sutada? (Sovantini capsules) were the first to be approved for sale in China, giving Chinese patients priority access to innovative drugs.
same time, Sovantini's U.S. listing applications have begun rolling through, and preparations for European listing permits are progressing steadily, promising to revolutionization of cancer treatments for patients around the world.
extraordinary speed, the sooner to meet the unfinished needs of Chinese patients to market, the faster the benefit of patients.
In order to benefit Chinese patients as soon as possible, and Huang medicine from production to logistics to marketing and other aspects of overcoming difficulties and overtime, hoping to reach this unique treatment to patients as quickly as possible to meet their unfinished needs.
According to and Huang Medicine Chief Marketing Officer Chen Hong introduced, in the production process, this half a month is in a race against time, but the pursuit of speed at the same time pay more attention to product quality, in raw materials, package materials, access testing, product control and other production management links and Huang Medicine have strict requirements to ensure that the standard can be met.
for the national landing of drugs, and yellow medicine has long been laid out ahead of time.
a team of about 400 people has been put in place, led by a leadership team with extensive experience in the commercialization of cancer products in China and neuroendocrine tumors, and currently covers more than 2,000 hospitals in 30 provinces or municipalities directly under the Central Government.
Sutaida (Sovantini capsule) as another production in Suzhou Park, and from the park to the national and Huang Medicine's second independent research and development of innovative drugs, is another strong proof of Huang Pharmaceutical's independent research and development capabilities.
After approval, the company with rapid response, mature production and commercialization capabilities, only half a month to complete the first shipment, in order to bring the best treatment for patients in the first time, with practical action to practice corporate social responsibility.
from Ayotte to Sutaida, and Huang Medicine took another solid first step towards serving Chinese patients in hospitals across the country.
, a biopharmaceutical company that has been innovating for 20 years, is doing so. The "fire speed" listing of (Sovantini capsule) is another major and landmark success for Huang Medicine and a new starting point.
Bioaversing Source: Biological Exploration Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mays Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here